@sanofi: What if cancer treatments could activate where they’re needed while limiting effects on normal tissues? That’s the idea behind conditional antibody technologies. Peter Luo, CEO of Adagene, explains how these antibodies are designed to activate preferentially in the tumor microenvironment, offering a potential approach to targeting cancer with greater precision. Watch the full conversation with Peter and Zandra Klippel, Therapeutic Area Head, Oncology Development at Sanofi, to explore the science behind conditional antibodies and how greater precision could help shape the future of cancer immunotherapy.

sanofi

Open In TikTok:

Region: FR

Wednesday 16 September 2026 15:00:01 GMT